Abstract: Objective: To evaluate the clinical efficacy and safety of Ibandronate and Bonefos for nonsmall celllung cancer (NSCLC) with bone metastases. Methods: A total of 86 NSCLC patients with bone metastases were randomlydivided into two groups: 44 in the Ibandronate group and 42 in the Bonefos group. The chemotherapy in both groups was Cisplatinbased. The therapeutic efficacy was evaluated after 2 cycles of treatment, with 21 days for each cycle. Results: The response rate of pain relief, improvement in daily living and effective rate on bone metastatic foci was 81.8% (36/44),68.2%(30/44) and 52.3%(23/44), respectively, in the Ibandronate group and 73.8%(31/42), 76.2%(32/42) and 45.2% (19/42), respectively, in the Bonefos group. No significant difference was found between the two groups (P>0.05). The side effects could be tolerated. Conclusion: The effects of Ibandronate and Bonefos on NSCLC patients with bone metastasescomparable. The administration of Ibandronate is more convenient.